论文部分内容阅读
目的观察早期肾癌根治术后行自体细胞因子诱导的杀伤(cytokine-induced killer,CIK)细胞治疗的临床疗效。方法选取解放军总医院2009年期间Ⅰ、Ⅱ期肾癌术后患者40例,治疗组20例采自体外周CIK细胞血进行CIK细胞扩增,采取静脉回输方法治疗;对照组20例术后未行其他治疗。观察CIK细胞培养前后细胞表型情况,对比治疗前及治疗后4周、24个月外周血T淋巴细胞亚群变化,记录不良反应情况、疗效和生活质量评定。结果 CIK细胞培养后可见CD3+CD8+、CD3+CD56+细胞较培养前显著增加(P<0.01);治疗后外周血CD3+、CD4+、CD4+/CD8+较治疗前升高(P<0.01)。治疗组20例:19例完全缓解,1例进展,患者治疗后生活质量提高,均无明显不良反应出现,疾病控制率95%;对照组20例:13例完全缓解,7例进展,疾病控制率65%(P<0.05)。结论自体CIK细胞治疗可以提高患者的免疫功能,延缓和阻止早期肾癌术后患者肿瘤的复发或转移,延长无病生存期,提高生活质量。
Objective To observe the clinical effect of cytokine-induced killer (CIK) cell therapy after radical nephrectomy in early stage of renal cell carcinoma. Methods Forty patients with stage I and II renal cell carcinoma were selected from PLA General Hospital during 2009, and 20 cases of peripheral blood CIK cells from the treatment group were enrolled in this study. CIK cells were expanded by intravenous infusion, and 20 cases in control group Other treatment line. The phenotypes of the cells before and after CIK cell culture were observed. The changes of T lymphocyte subsets in peripheral blood before and 4 weeks and 24 months after treatment were compared. Adverse reactions, curative effects and quality of life were recorded. Results After CIK cells were cultured, CD3 + CD8 + and CD3 + CD56 + cells were significantly increased (P <0.01). The levels of CD3 +, CD4 + and CD4 + / CD8 + in peripheral blood of CIK cells were significantly increased after treatment (P <0.01). The treatment group of 20 patients: 19 cases of complete remission, 1 case of progress, the quality of life of patients improved after treatment, no significant adverse reactions, the disease control rate of 95%; control group of 20 patients: 13 cases of complete remission, 7 cases of progression, disease control The rate was 65% (P <0.05). Conclusions Autologous CIK cell therapy can improve immune function, delay and prevent the recurrence or metastasis of tumor in patients with early stage renal cell carcinoma, prolong disease-free survival and improve quality of life.